Breast Cancer


For the first time, a randomized clinical trial has shown significant tumor shrinkage with a phosphoinositide-3-kinase (PI3K) inhibitor in patients with estrogen receptor (ER)-positive, HER2-negative early breast cancer. The phase 3 study LORELEI compared neoadjuvant therapy with letrozole plus placebo versus letrozole plus taselisib, a PI3K inhibitor, in this patient population. Read Article ›

Why CDK4/6 Inhibitors Are Effective in HR-Positive Metastatic Breast Cancer
Dr Hope Rugo cites that CDK4/6 inhibitors play a critical role in estrogen signaling and can be very effective in treating metastatic breast cancer when used in combination with hormone therapy. Read Article ›

CDK4/6 Inhibitors vs Chemotherapy for Patients with Metastatic Breast Cancer
Dr. Hope Rugo attempts to dispel this misconception, citing that endocrine therapy and CDK4/6 inhibitors are well tolerated and don’t have the intensive side effects associated with chemotherapy. Read Article ›

What Differentiates Abemaciclib, Ribociclib, and Palbociclib?
Dr Hope Rugo addresses some of the main differences between the 3 CDK4/6 inhibitors that are FDA-approved in HR-positive metastatic breast cancer. Read Article ›

Disease Progression with a CDK4/6 Inhibitor plus an Aromatase Inhibitor
Hope S. Rugo, MD, describes how she would treat a patient with HER-positive metastatic breast cancer that has progressed with a CDK4/CDK6 inhibitor plus an aromatase inhibitor. Read Article ›

HER2-Positive Breast Cancer and CDK4/6 Inhibitors




Want more Breast Cancer-related news?

Sign up for the OPM weekly e-Newsletter!

Enter your contact information below to recieve weekly oncology news & updates.

Page 4 of 6

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: